Laura M Dember, MD
University of Pennsylvania Perelman School of Medicine
Center for Clinical Epidemiology and Biostatistics
Blockley Hall, Office 920
423 Guardian Drive
Philadelphia, PA 19104
Yale College, New Haven, CT, 1984.
Yale School of Medicine, New Haven, CT, 1988.
Description of Clinical ExpertiseDr. Dember has more than 20 years of experience as a general nephrologist and has internationally-recognized expertise in the systemic amyloidoses, a group of rare disorders that often affect the kidneys. She has been involved in the development of novel treatments for AL and AA amyloidosis, and is a member of the University of Pennsylvania multidisciplinary amyloidosis program that evaluates and treats patients with all types of amyloidosis and paraprotein disorders.
Description of Other ExpertiseDr. Dember is a Deputy Editor of the American Journal of Kidney Diseases and has served on multiple NIH grant review panels and committees of the American Society of Nephrology.
Description of Research ExpertiseDr. Dember conducts patient-oriented research including mechanistic studies and clinical trials in chronic kidney disease and end-stage renal disease (ESRD). She has particular interests in hemodialysis vascular access and interventions to improve clinical outcomes in end-stage renal disease. Her research is funded by the National Institutes of Health. Dr. Dember is Principal Investigator for the Data Coordinating Center of the NIDDK Hemodialysis Novel Therapies Consortium which is conducting early phase clinical trials targeting ESRD-associated inflammation and cardiovascular disease, and she is the Principal Investigator for the "TiME Trial", a large, pragmatic cluster-randomized clinical trial being conducted through the NIH Health Care Systems Research Collaboratory. The TiME Trial has enrolled more than 7200 participants at 266 dialysis units throughout the United States and uses highly centralized implementation and data collection approaches that leverage the infrastructure and clinical care delivery systems of dialysis provider organizations. Dr. Dember is also a principal investigator for the NIDDK Hemodialysis Fistula Maturation Study -- a multicenter observational cohort study designed to elucidate predictors and mechanisms of arteriovenous fistula maturation, and she is a member of the Scientific and Data Coordinating Center for the NIDDK Chronic Renal Insufficiency Cohort Study.
Selected PublicationsTong Xiaoyong, Hou Xiuyun, Wason Christopher, Kopel Tal, Cohen Richard A, Dember Laura M: Smooth Muscle Nitric Oxide Responsiveness and Clinical Maturation of Hemodialysis Arteriovenous Fistulae. Am J Pathol 187(9): 2095-2101, Sep 2017.
Kopel Tal, Kaufman James S, Hamburg Naomi, Sampalis John S, Vita Joseph A, Dember Laura M: Endothelium-Dependent and -Independent Vascular Function in Advanced Chronic Kidney Disease. Clin J Am Soc Nephrol Aug 2017.
Alpers CE, Imrey PB, Hudkins KL, Wietecha TA, Radeva M, Allon M, Cheung AK, Dember LM, Roy-Chaudhury P, Shiu Y-T, Terry CM, Farber A, Beck GJ, Feldman HI, Kusek JW, Himmelfarb J. : Histopathology of veins at time of creation of arteriovenous fistulas: findings from the Hemodialysis Fistula Maturation Study. J Am Soc Nephrol 28(10): 3076-3088, October 2017.
Cheung AK, Imrey PB, Alpers CE, Robbin ML, Radeva M, Larive B, Shiu Y-T, Allon M, Dember LM, Greene T, Himmelfarb J, Roy-Chaudhury PR, Terry CM, Vazquez MA, Kusek JW, Feldman HI: Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study. J Am Soc Nephrol 28(10): 3005-3013, October 2017.
Courtright KR, Madden V, Gabler NB, Cooney E, Kim J, Herbst N, Burgoon L, Whealdon J, Dember LM, Halpern SD: A randomized trial of expanding choice sets to motivate advance directive completion. Med Decis Making August 2016 Notes: pii: 0272989X16663709 (epub ahead of print).
Sawinski Deirdre, Lim Mary Ann, Cohen Jordana C, Locke Jayme E, Weiss Brendan, Hogan Jonathan J, Dember Laura M: Patient and Kidney Allograft Survival in Recipients with End Stage Renal Disease from Amyloidosis. Transplantation 102(2): 300-309, February 2018.
Dember LM, Archdeacon P, Krishnan M, Lacson E, Ling SM, Roy-Chaudhury P, Smith KA, Flessner MF: Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative. J Am Soc Nephrol 27(10): 2955-2963, October 2016.
Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR, Martin KJ, McNei JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI, Dialysis Access Consortium (DAC) Study Group: Effect of dipyridamole plus aspirin on hemodialysis graft patency N Engl J Med 360: 2191-2201, 2009.
Dember LM, Beck GJ, Allon M, Delmez J, Dixon BS, Greenberg A, Himmelfarb J, Vazquez VA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI. Dialysis Access Consortium (DAC) Study Group: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized, controlled trial. JAMA 299: 2164-71, 2008.
Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butriemene I, Livneh A, Lesnyak O, puechal X, Lachmann H, Obici L, Balshaw R, Garceau D, Hauck W. Skinner M: Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356: 2349-60, 2007.